Real-world utilization of bispecific antibodies for treatment of diffuse large B-cell lymphoma (DLBCL) in the US community oncology setting

Trends in Real-World Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals

Clinical Profiles, Treatment Characteristics and Outcomes Among Newly Diagnosed Hodgkin Lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting

Background: Women with early-stage breast cancer (eBC) who have inherited BRCA1 or BRCA2 mutations (gBRCAm) are typically diagnosed at a younger age and often require more intensive treatment. In the randomized, double-blind OlympiA trial of HER2-negative (HER2–) gBRCAm patients, olaparib, a targeted poly (ADP-ribose) polymerase inhibitor (PARPi), significantly improved invasive disease free survival (IDFS), distant disease free survival (DDFS) and overall survival (OS) and was subsequently approved for adjuvant treatment of gBRCAm HER2– high-risk eBC patients. This study examined the real-world patient characteristics, treatment patterns and clinical outcomes by gBRCA status among patients with HER2– eBC in a US community oncology setting prior to olaparib US approval for treatment of eBC. Methods: This retrospective observational study used chart review data from The US Oncology Network's iKnowMed database to examine adult patients diagnosed with HER2– eBC (stage I-III) initiating systemic neoadjuvant or adjuvant therapy with chemotherapy and/or endocrine therapy between January 1, 2012 and December 31, 2018. Patients with valid gBRCAm test results (all gBRCAm and randomly selected BRCAwt patients) were included and followed through December 31, 2021. Patients were excluded if they had HER2+ tumors and progressed to stage IV within 6 months after initiation of neoadjuvant therapy or were diagnosed with another primary cancer. Descriptive analyses assessed patient characteristics. Kaplan Meier methods and multivariate Cox proportional hazard models (CPHM) were used to evaluate IDFS, DDFS and OS by gBRCA status and by HR+/HER2– or TNBC eBC subsets. Results: Among 298 BC patients meeting initial criteria, 42% had gBRCAm (n=124, 43% hormone receptor positive [HR+], 56% triple-negative BC [TNBC], 1% unknown), and 58% had gBRCAwt (n=174, 74% HR+, 22% TNBC). Median (interquartile) age at surgery was numerically lower in gBRCAm (45 [36,55] years) than gBRCAwt (48 [41,55] years) patients. A numerically higher proportion of gBRCAm patients received neoadjuvant therapy compared with gBRCAwt (Neoadj: gBRCAm 37.1% vs gBRCAwt 12.6%) but the reverse was true for adjuvant (Adj: gBRCAm 42.7% vs gBRCAwt 65.5%) and neoadjuvant + adjuvant use was numerically similar (Neoadj+Adj: gBRCAm 20.1% vs gBRCAwt 21.8%). The majority of TNBC patients received neoadjuvant therapy while the majority of HR+ patients received adjuvant therapy (Neoadj: TNBC 51.4% vs HR+ 6.6%, Adj: TNBC 29.0% vs HR+ 71.4%, Neoadj+Adj: TNBC 19.6% vs HR+ 22.0%). Median IDFS, DDFS, and OS in both study cohorts were not reached. Median follow-up from surgery was < 5 years (overall 59.0 months; gBRCAm 50.6 months; gBRCAwt 61.3 months). At 60 months, in gBRCAm and gBRCAwt respectively, estimated IDFS were 85.5% and 90.9%, estimated DDFS 88.1% and 92.2%, and estimated survival 91.9% and 95.2%. At 60 months, in HR+/HER2– and TNBC respectively, estimated IDFS were 92.4% and 81.2%, estimated DDFS 93.9% and 85.7%, and estimated survival 96.3% and 90.9%. CPHM results showed that risks of invasive disease (HR 1.74; 95% CI 0.83-3.64; p=0.15), distant disease (HR 1.24; 95% CI 0.50-3.07; p=0.65) and death (HR 1.79; 95% CI 0.52-6.13; p=0.353) were similar between gBRCAm and gBRCAwt patients. Between HR+/HER2– and TNBC patients, risks of invasive disease (HR=0.63; 95% CI 0.21-1.89; p=0.41), distant disease (HR=0.42; 95% CI 0.11-1.67; p=0.22) and death (HR 0.48; 95% CI 0.09-2.70; p=0.41) were similar. Conclusions: This real-world chart review study of data through 2021 (before PARPi approval for eBC) with limited follow up of 5 years found that gBRCAm patients had a numerically shorter survival (IDFS, DDFS and OS) than gBRCAwt, but this difference was not statistically significantly different. Given that the follow-up period was too short to draw conclusions, further studies examining clinical outcomes over a longer follow-up period after approval of PARPi may be of interest. Citation Format: Jay Andersen, Jagadeswara Earla, Nicole Fulcher, Juliet Ndukum, Nicholas J Robert, Mark Robson, Weiyan Li, Jaime Mejia. Real world treatment patterns and clinical outcomes by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer in the US community oncology setting: a retrospective observational chart-review study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-17-06.

Of the >1.6 million people diagnosed with cancer in the US each year, >60% are diagnosed after symptomatic presentation, including nonspecific s/sx. These nonspecific s/sx may cause pts to undergo unnecessary diagnostic evaluation while the possibility of cancer and search for its origin is explored, causing delayed treatment and poor outcomes. Additionally, pts who do not have cancer are often subjected to various undirected/misdirected procedures due to initial cancer suspicion. Our objective was to examine pt characteristics, diagnostic journey, and cancer incidence of pts with nonspecific s/sx within The US Oncology Network. This retrospective observational cohort study included pts aged ≥40 with ≥1 of the following nonspecific s/sx in their problem list at their first visit within The US Oncology Network (index date) during the identification period from 1/1/2016 to 12/31/2020: anemia, venous thromboembolism, general malaise, weight loss, nonspecific abdominal symptoms, new and unexplained breathlessness, unexplained worsening pain, and abnormal lab test results. Pts were excluded if diagnosed with any cancer (except basal cell carcinoma and squamous cell carcinoma skin cancer) within 3 years prior to or on index date. Pts were followed longitudinally with data from electronic health records for initial cancer diagnosis (dx), death, end of study observation period, or 12 months, whichever occurred first. Demographic and clinical characteristics were assessed descriptively. 103,984 pts were identified. The median age was 65.7, 64% were female, 65% were White, 41% were obese, 47% were never smokers, and 48% were from a southern practice region. 6,774/103,984 pts (7%) were diagnosed with cancer and 6,537/6,774 (97%) with 1 primary cancer: 3,825/6,537 (59%) were diagnosed with a hematologic malignancy and 2,712/6,537 (41%) with a solid tumor cancer. Among pts diagnosed with primary solid tumors, 31% had gastrointestinal, 15% genitourinary, 15% respiratory, 13% breast, and 11% gynecologic cancer. Among pts diagnosed with cancer, median time to cancer dx after being referred to secondary care within The US Oncology Network with nonspecific s/sx was >5 wks (solid: >7 wks; hematologic: >4 wks); by 17 and 34 wks, 75% and 90% of pts received a cancer dx, respectively. Within this population of pts most frequently presenting with nonspecific hematologic s/sx and subsequent cancer dx, 40% were diagnosed with solid tumor cancers within 1 year. This speaks to the unmet need for more tools such as a multi-cancer detection test that could aid in detection of multiple cancers and faster diagnostic resolution of nonspecific s/sx. Given the impact of delayed cancer dx and timely treatment on outcomes, such a test could potentially substantially improve cancer care and diagnostic evaluations. Citation Format: Christopher Benton, Ding He, Karen Todoroff, Marie V. Coignet, Ying Luan, Kathryn N. Kurtzman, Ira Zackon. Patient (pt) characteristics, diagnostic journey, and cancer enrichment among pts with nonspecific signs and/or symptoms (s/sx) in the US community oncology setting: a real-world retrospective study. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6752.

Background: TNBC is an aggressive subtype of breast cancer with limited targeted therapies. Black women have twice the incidence of TNBC compared to White women and within TNBC, Black women have worse outcomes than White women. Differences in both tumor biology of TNBC and social determinants of health (SDOH) play a role in observed disparities. The focus of this study is to evaluate SDOH factors associated to differences in the use of neoadjuvant chemotherapy (NC) in Black and White women in the US community oncology setting. Methods: This study was a retrospective, observational, cross-sectional design and used iKnowMed SM EHR data from the The US Oncology Network. Patients diagnosed with TNBC between 03/31/2017 and 09/30/2021 with stages II-III disease of tumor size ≥ 2cm (T2 or higher) were included. The index date was date of TNBC diagnosis and records were assessed from 6 months pre- to 6 months post-diagnosis for NC initiation. Univariable and multivariable logistic regression was conducted to evaluate impact of self-reported race on NC. Age, stage, BMI, insurance, area deprivation index (ADI), size of practice represented by physician count and geographical region, were studied in their mediating and moderating effects1 on the relationship between race and NC treatment. Results: Of the 3321 patients with TNBC identified in this study, 1969 self-reported white and 494 self-reported black (80% and 20% respectively). In multivariable regression accounting for all variables, Black race (OR = 1.57, 95% CI [ 1.02, 2.44], p=0.04), younger age, more advanced stage, obesity, non-Medicaid insurance, and West region, were all found to be positively associated with use of NC. Higher physician count was nominally associated, (p = 0.07). ADI was not found to be associated to NC. Mediator and moderator analysis for the relationship between race and NC showed that only stage and ADI variable inclusion in the model are required for the positive association between black race and NC. This is driven by a significant interaction between ADI and stage (p = 0.027) which differed for Black and White women. Mainly, for Black women ADI is positively associated to NC treatment in stage IIA, but negatively associated in all other stages (interaction term, p = 0.033). For White women, ADI is negatively associated to NC treatment in all stages. Only Black women with stage IIA tend to be treated more instead of less with NC in areas of greater deprivation (greater ADI). BMI presents nominal interactions with both race and stage, where obesity was more strongly associated with NC treatment in Black women (p = 0.088) and in stage IIA (p = 0.086). All other variables presented association to NC treatment without mediation or moderation of the race effect and without detectable differences across stages. Conclusions: Black women with stage IIA appear to be a special subgroup of TNBC patients for whom treatment with NC increases with ADI. Increased ADI generally results in less standard of care treatment; this is observed in this study for White women overall and for Black women in stages > IIA. Black women in areas of greater deprivation with stage IIA disease, may be perceived to be presenting with more aggressive disease and thus offered NC preferentially. This result lends support to the hypothesis that young black women present with a distinct, more aggressive subtype of TNBC in the early stages. Mediator and moderator analyses are important tools in elucidating the relationships between factors underlying racial disparities in both care and outcomes. 1. Hayes AF, Rockwood NJ. Regression-based statistical mediation and moderation analysis in clinical research: Observations, recommendations, and implementation. Behav Res Ther. 2017 Nov;98:39-57. Odds ratios for multivariable analysis –insert figure image– Race, stage and ADI –insert figure image– Race and BMI in stage IIA –insert figure image– Citation Format: Paola Raska, Joseph Dye, Nicholas J Robert, Angel Kidd, Michael Danso. Race and neoadjuvant treatment of triple negative breast cancer (TNBC) in the US community oncology setting [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO3-03-10.

The Evolution of Treatment Patterns for Chronic Lymphocytic Leukemia (CLL): Trends in the US Community Oncology Setting from 2015 to 2024

e12535 Background: Germline BRCA mutations (gBRCAm) are associated with a higher risk of breast cancer at a younger age. Generally, gBRCA gene testing is performed in patients perceived as high risk for gBRCAm. Olaparib, a targeted poly (ADP-ribose) polymerase inhibitor (PARPi), has significantly improved overall survival (OS) in the randomized, double-blind OlympiA trial of patients with HER2-negative gBRCAm and was subsequently approved for the adjuvant treatment of patients with gBRCAm HER2-negative high-risk early breast cancer (eBC) treated with neoadjuvant or adjuvant chemotherapy. This study examines the real-world patient characteristics, treatment patterns and OS by gBRCA status among patients with HER2-negative eBC in a US community oncology setting prior to olaparib US approval for treatment of eBC. Methods: This retrospective observational study used structured data from The US Oncology Network's iKnowMed database. Adult patients were included if diagnosed with HER2-negative eBC (stage I-III) and if they initiated systemic neoadjuvant or adjuvant therapy between January 1, 2012-December 31, 2018 (followed through December 31, 2021). Patients were excluded if they progressed to stage IV within 6 months after neoadjuvant treatment or were diagnosed with another primary cancer. Descriptive analyses assessed patient characteristics, early-stage systemic treatments and OS among patients by gBRCA status. Results: Among 19,258 patients with BC meeting initial criteria, 1436 (7.5%) had a documented gBRCA test result. Among them, 10% had gBRCAm (n = 141, 43% hormone receptor positive [HR+], 57% triple-negative BC [TNBC]), 90% BRCAwt (n = 1294, 70% HR+, 30% TNBC), and 1 had a variant of uncertain significance. Median age at surgery was numerically lower in gBRCAm (43 years) than gBRCAwt (48 years) patients. Treatments included neoadjuvant-only therapy (gBRCAm 58%; gBRCAwt 34%), adjuvant-only therapy (gBRCAm 42%; gBRCAwt 66%) and both neoadjuvant and adjuvant therapy (gBRCAwt 0.1%). Median OS in both study cohorts was not reached. Median follow-up from surgery was less than 4 years (gBRCAm 47 months; gBRCAwt 46 months). At 48 months, estimated survival was 95% in gBRCAm and 94% in gBRCAwt patients. Conclusions: In this cohort of patients with HER2-negative eBC, among the 7.5% with a documented gBRCA result, 10% were identified with gBRCAm, reinforcing the need for gBRCA testing. Using structured real-world data through 2021 (prior to PARPi approval for eBC) with limited follow-up of < 4 years, our study found that OS by gBRCA status was similar among patients with HER2-negative eBC. Our further research with chart review data containing granular clinical information looking at intermediate endpoints such as recurrence in eBC is under way.

Background: One-third of breast cancer (BC) cases in BRCA1-mutated (BRCA1m) patients are classified as triple-negative breast cancer, an aggressive cancer prone to early onset and high risk of metastasis. 70% of BC cases in BRCA2-mutated (BRCA2m) patients are classified as hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-). Differences in patients with BRCA1m and BRCA2m tumors suggest the need for targeted screening and treatment strategies based on genetic risk profiles. Olaparib, a poly ADP-ribose polymerase inhibitor, was approved in 2022 for adjuvant treatment in patients with germline BRCAm, HER2-, high-risk early BC (eBC) with prior chemotherapy, following the significant survival benefit seen in the OlympiA trial. It is a priority to understand how the introduction of targeted therapies like olaparib affects clinical management – including BRCA testing – and outcomes in eBC. With two years of post-approval real-world experience, we conducted a preliminary landscape assessment describing eBC patients prescribed olaparib or another adjuvant therapy with respect to patient characteristics and BRCA testing prevalence. Methods: This was a retrospective observational cohort study characterizing HER2- eBC patients treated with olaparib or other adjuvant therapy in US community oncology clinics utilizing the iKnowMed electronic health record. Adult patients (≥18 years) diagnosed from 1 March 2018 to 31 January 2024 were eligible for inclusion and followed until last patient contact or death. Descriptive analyses evaluated patient characteristics at diagnosis, as well as BRCA testing characteristics, both overall and by treatment (initiation of olaparib or completion of non-olaparib adjuvant therapy). Results: 250 patients (134 olaparib, 116 non-olaparib) were included and followed for a median (interquartile range [IQR]) of 26.4 (16.1, 37.9) months. Olaparib users were younger at initial diagnosis (mean (standard deviation [SD]) age of 45.8 [12.2] years versus 61.4 [14.4] years among non-olaparib users), and all patients were predominantly White (61.9% olaparib, 57.8% non-olaparib) and non-Hispanic (80.6% olaparib, 76.7% non-olaparib). Where pathologic stage was documented, most patients were diagnosed at Stage II or lesser disease (76.8% olaparib, 86.0% non-olaparib) with a histology of ductal carcinoma (87.3% and 85.3%, respectively). Notably, 68.7% of olaparib users were diagnosed with G3 high grade tumors, versus only 32.8% of non-olaparib users. All olaparib users received a BRCA test (98.5% of patients BRCAm and 1.5% negative). Among the 60.3% of non-olaparib users tested, 23.3% were BRCAm. Conclusions: This study is one of the first to report the real-world experience of eBC patients immediately prior to and following olaparib approval. All olaparib users received a BRCA test, indicating promising results with respect to appropriate use of olaparib in only BRCA-tested patients. The analysis also found that while a high number of non-olaparib users received a BRCA test and were BRCAm, these results may indicate a potential lost opportunity for both universal BRCA testing and for BRCA-mutated patients to receive targeted therapy. However, future analyses will assess the timing of BRCA testing with respect to the availability of olaparib in this patient subgroup. Future analyses may characterize potential changes in BRCA testing patterns in the post-olaparib setting, which will facilitate the optimization of targeted treatment plans. Lastly, as the ultimate goal is to assess impact of olaparib on eBC patient management, including improvements in survival, a formal comparative assessment of key clinical outcomes in olaparib versus other adjuvant therapies should be conducted once additional follow-up time is available. Citation Format: Matthew Monberg, Kathryn Mishkin, Lauren Stevens, Daphne Derose, Qixin Li, Xiaoqing Xu, Rosa Banuelos, Juliet Ndukum, Lisa Herms, Paul Conkling, Jay Andersen. Real-world characteristics and BRCA testing among HER2- early breast cancer patients receiving olaparib or other adjuvant therapy in the US community oncology setting [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P5-10-24.

Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting

11005 Background: The rise of EO-CRC in individuals under the age of 50 presents a major public health challenge, as these patients may encounter unique barriers to both screening and treatment. Understanding the drivers and implications of EO-CRC is crucial, and real-world data (RWD) can serve as a valuable tool by offering insights into evolving diagnostic, utilization, and practice landscapes, with robust information on social determinants of disease burden. Building on existing disparity concerns, this study leveraged RWD from a large, nationally diverse network of US community oncology practices to describe the SDOH and outcomes of patients with EO-CRC. Methods: This retrospective observational cohort study examined adult CRC patients within The US Oncology Network and non-Network practices, encompassing over 2,500 community-based providers treating more than 1.4 million patients annually. All patients diagnosed with CRC between 2000 and 2024 were included; patients were categorized as EO-CRC if they were < 50 years at first diagnosis and average-onset (AO)-CRC otherwise. Patient characteristics were sourced from iKnowMed, an oncology-specific electronic health record system, and descriptively summarized. Overall survival (OS) was assessed from diagnosis using Kaplan-Meier methods. Results: A total of 104,281 patients were identified, including 14,611 (14%; median age: 44 years) with EO-CRC and 89,670 (86%; median age: 67 years) with AO-CRC. Patients in the EO-CRC cohort were more likely to be Black (11% vs. 8%), American Indian or Alaska Native race (1.3% vs. 0.9%), of a documented race other than White (20% vs. 15%), and of Hispanic/Latino ethnicity (11% vs. 8%) versus the AO-CRC cohort. Few of EO-CRC (11%) and AO-CRC (10%) patients were current smokers at time of diagnosis. More than one-third of EO-CRC group was obese (36%), slightly higher than in AO-CRC (31%). EO patients were more commonly located in urban areas (69% vs. 63% of AO patients). Among 2,810 patients with Distress Thermometer data, EO-CRC patients were more likely to report high or moderate distress (29% vs. 22%) and less likely to report low distress (71% vs. 78%). 5-year OS probability was 72% (95% CI: 71-73) for EO-CRC and 64% (95% CI: 63-64) for AO-CRC. Conclusions: In one of the largest cohorts of patients with EO-CRC to date, this study confirmed that EO-CRC is an emerging concern within the US community oncology setting, particularly regarding heightened disparities in race, ethnicity, and lifestyle factors. EO patients may face unique burdens related to timely screening and diagnosis, necessitating tailored and cross-disciplinary approaches to their care, and warranting additional investigation into social and clinical drivers of survival outcomes to improve long-term prognosis.

Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting

e18805 Background: Evaluation of endpoints in oncology research requires accurate assessment of patients’ vital status. For real-world investigations of cancer populations, comprehensive capture of patients’ death dates may require several data sources. The intent of this evaluation was to assess capture of documented death dates across multiple datasets in the US community oncology setting. Methods: This was a retrospective observational study of adult patients with GBM or mPC who initiated treatment between 1 January 2019 and 31 December 2019 within The US Oncology Network. Patient demographic, clinical and treatment characteristics were sourced from an electronic health record (EHR) database, iKnowMed (iKM). Patients were followed until January 2023 with death dates captured from the iKM EHR (structured and unstructured fields), the iKM claims database, the Social Security Administration’s Death Master File, as well as a commercially available mortality dataset from Datavant comprised of obituary, claims and government records. Chart review was used to confirm if patients were alive on 15 January 2023. The overall capture rate of death information from each source was evaluated descriptively. Agreement was assessed using two approaches: 1) as death dates that were an exact match between sources and 2) as death dates that occurred within 30 days of each other and/or within the same month. Results: A total of 173 patients with GBM (median age 65 years, median follow-up time 12.0 months) and 990 patients with mPC (median age 68 years, median follow-up time 7.1 months) were included. Across all sources, 91.1% of the pooled population had at least one documented death date or were confirmed to be alive (85.5% and 92.1% of patients with GBM and mPC, respectively). Among patients with full day-month-year death dates from at least 2 sources (n = 835), 95.4% of death records were matched on the exact death dates. Among patients with any death record from at least 2 sources (n = 852), 99.3% of death records were matched within 30 days of each other or within the same month. Conclusions: The findings of this study describe the capture rate of mortality and vitality status in the US community oncology setting. Future analyses are planned to augment these assessments of concordance, sensitivity, specificity, positive predictive value and negative predictive value across the sources with comparison to death dates captured by the National Death Index. These insights are important for development of composite mortality databases, comprised of death information from multiple sources using appropriate tokenization and overlap methodologies.

Background: The treatment landscape for women with HR+/HER2- advanced and metastatic breast cancer (A/MBC) is changing as new agents are being combined with more established treatments to achieve greater efficacy in combating resistant and unresponsive disease. The present study is designed to describe patient characteristics, treatment patterns, and clinical outcomes in a cohort of women with HR+/HER2- A/MBC treated with palbociclib plus aromatase inhibitor (P+AI) or palbociclib plus fulvestrant (P+FV) in the US community oncology setting. Methods: Retrospective medical record data from adult women diagnosed with HR+/HER2- A/MBC who initiated P+AI or P+FV for treatment of A/MBC on or after February 3, 2015 were collected from the Vector Oncology Data Warehouse, a network comprised of 10 community oncology practices across the US. Descriptive analyses were performed on patient characteristics, treatment patterns, and clinical outcomes. Time to event outcomes (progression-free rate (PFR) and survival rate (SR)) at 12 (PFR-12, SR-12) and 24 (PFR-24, SR-24) months for the P+AI combination as first line endocrine therapy and 12 and 18 months for the P+FV combination as treatment following prior endocrine based therapy in either the adjuvant or metastatic setting. Results: Among 304 patients who received palbociclib combination therapy, 281 (92.4%) received it per labeled indication. Of the 281 on-label users, the focus of reporting here, 233 (82.9%) received P+AI as their initial endocrine therapy after A/MBC diagnosis; 48 (17.1%) received P+FV after prior endocrine therapy for breast cancer. Patient mean age (SD) was 63.1 (11.4) and 68.2 (10.2) years for patients receiving P+AI and P+FV, respectively. Patients were predominantly white (74.2% for P+AI and 77.1% for P+FV patients).The initial dosing for palbociclib was 125mg/day in 85.4% (n=199) of P+AI and 79.2% (n=38) of P+FV patients. Among patients who received P+AI, PFR-12 was 69.8% and PFR-24 was 46.8% with median follow up time of 10.8 months and 36.8% of progression events. The SR-12 was 89.8% and SR-24 was 71.4%. For patients who received P+FV, PFR-12 was 43.5% and PFR-18 was 39.9% with a median follow up time of 7.6 months and 50.0% of progression events. The SR-12 was 76.3% and SR-18 was 65.0%. Conclusions: This study provides real-world assessment of treatment patterns and clinical outcomes of patients with HR+/ HER2- A/MBC who received palbociclib in combination with an AI or a FV in US community oncology settings. These findings demonstrate the benefit of palbociclib combination therapy in a diverse real world population. Sponsor: Pfizer, Inc. Citation Format: Trocio J, Lin J, Fisher MD, Hu N, Davis C, McRoy L, Walker MS, Iyer S. Real-world treatment patterns and clinical outcomes with palbociclib combination therapy received in US community oncology practices [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-29.

Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting

Demographics and Mortality of Patients Diagnosed with Multiple Myeloma Treated in the US Community Oncology Setting from 2018 to 2023: Assessing Trends in the Pre-, Peri- and Post-Pandemic Eras